Table 1 Demographic and clinical data of the cohort of 66 Salivary duct carcinoma (SDCa).
From: Molecular patterns in salivary duct carcinoma identify prognostic subgroups
Feature | No. of patients(N = 66) |
|---|---|
Age in years, median (IQR) | 63.1 (56.9–71.4) |
Range, years | 24.7–92.0 |
Age (years), N (%) | |
<50 | 8 (12.1) |
51–60 | 18 (27.3) |
61–70 | 20 (30.3) |
71–80 | 11 (16.7) |
>80 | 9 (13.6) |
Sex, N (%) | |
Female | 18 (27.3) |
Male | 48 (72.7) |
Smoking status, N (%) | |
Never smoker | 19 (28.8) |
Moderate (<50 pack years) | 15 (22.7) |
Heavy (>50 pack years) | 8 (12.1) |
Unknown | 24 (36.4) |
Location of primary tumor, N (%) | |
Parotid gland | 54 (81.8) |
Submandibular gland | 11 (16.7) |
Sublingual gland | 1 (1.5) |
Minor salivary gland | 0 (0) |
Tumor arising from pleomorphic adenoma, N (%) | |
Yes | 7 (10.6) |
No | 59 (89.4) |
T-stage, N (%)* | |
1 | 14 (21.2) |
2 | 19 (28.8) |
3 | 15 (22.7) |
4 | 18 (27.3) |
N-stage, N (%)* | |
0 | 22 (33.3) |
1 | 7 (10.6) |
2 | 33 (50.0) |
3 | 1 (1.5) |
Unknown | 3 (4.5) |
M-stage, N (%)* | |
0 | 61 (92.4) |
1 | 4 (6.1) |
Unknown | 1 (1.5) |
Overall stage, N (%)* | |
I | 7 (10.6) |
II | 7 (10.6) |
III | 12 (18.2) |
IV | 40 (60.6) |
Initial treatment, N (%) | |
Surgery alone | 16 (24.2) |
Surgery and (chemo-) radiotherapy | 49 (74.2) |
Radiotherapy alone | 1 (1.5) |
Recurrence after initial treatment, N (%) | |
No persistence or recurrence | 35 (53.0) |
Recurrence after initial treatment | 31 (47.0) |
Survival status at last census, N (%) | |
Alive, no evidence of disease | 32 (48.5) |
Alive with disease | 6 (9.1) |
Died of disease | 23 (34.8) |
Died of other cause | 5 (7.6) |
Follow-up time in months, median (IQR) | 38.2 (12.9, 64.5) |
